ECCI PARTICIPATING INSTITUTIONS

Scientific program

Download the ECCI 2018 program (PDF)
Monday May 14th
08:30 Welcome. ECCI and Partners.
08:30 ECCI : mission and activities.
Arnaud MARCHANT, Belgium

08:40 Partnership with ESCV.
Pamela VALLELY, UK

08:50 Global CMV Network.
Laura GIBSON, USA

09:00 Presentation by patient groups • Anne-Hélène LABISSY, France; Francesca LOVATO, Italy; Elizaveta PADALKO, Belgium
09:20 Burden of congenital CMV infection • Chairs: Graciela ANDREI, Belgium; Paulo PAIXÃO, Portugal
09:20 CMV, pregnancy, ethics : the links ?
Luc ROEGIERS, Belgium

09:45 Risk perception and recourse to pregnancy termination due to maternal cytomegalovirus infection.
Annalisa CARAPEZZI, Italy

10:00 Coffee break
10:30 Burden of congenital CMV infection (Part 2) • Chairs: Graciela ANDREI, Belgium; Paulo PAIXÃO, Portugal
10:30 Health and economic burden of congenital CMV infection in Europe.
Suzanne SMIT, Belgium

10:55 The economic cost of congenital CMV in the UK.
Sharon WOOD, UK

11:10 Worldwide cytomegalovirus seroprevalence: a systematic review and meta-analysis.
Mohamed ZUHAIR, UK

11:25 Diagnosis of maternal, fetal and neonatal infections • Chairs: Jos VAN ACKER, Belgium; Theresia POPOW-KRAUPP, Austria; Tiziana LAZZAROTTO, Italy
11:25 Diagnosis of maternal infection.
Marianne LERUEZ-VILLE, France

11:50 Combination of line immunoassays Mikrogen recomLine CMV IgG and recomLine CMV IgG avidity helps to date the onset of CMV primary infection.
Marie-Luce DELFORGE, Belgium

12:05 Kinetics of human cytomegalovirus IgG avidity maturation: a serological marker of vertical transmission.
Milena FURIONE, Italy

12:20 Correlation between type of matenal CMV infection (primary versus non-primary) and outcome. A systematic review and Incidence of SNHL in infants born post maternal non-primary CMV infection. Implications for routine maternal prenatal screening.
Vassiliki PAPAEVANGELOU, Greece

12:40 Lunch and posters
14:10 Diagnosis of maternal, fetal and neonatal infections (Part 2) • Chairs: Jos VAN ACKER, Belgium; Theresia POPOW-KRAUPP, Austria; Tiziana LAZZAROTTO, Italy
14:10 Diagnosis of fetal and neonatal infections.
Pamela VALLELY, UK

14:35 Comparative study of 2 screening techniques for cCMV infection: viral isolation in urine and PCR for CMV on the Guthrie card.
Annelies KEYMEULEN, Belgium

14:50 PICCSA Study. Prevalence and clinical manifestations of congenital cytomegalovirus infection in a screening program in Madrid.
Daniel BLÁZQUEZ-GAMERO, Spain

15:05 Treatment and prognosis of fetal and paediatric infections • Chairs: Catherine DONNER, Belgium; Giuliana SIMONAZZI, Italy;Dana WOLF, Israel
15:05 Treatment and prognosis of fetal infection.
Yves VILLE, France

15:30 New insights into the pathophysiology of hyperechogenic bowel in CMV infected fetuses.
Liliana GABRIELLY, Italy

15:45 Predictive value of blood parameters in cytomegalovirus (CMV) infected fetuses with sonographic findings according to the trimester of pregnancy at cordocentesis.
Anna GONCE, Spain

16:00 Fetal treatment for congenital cytomegalovirus infection: Study of the placental transfer of Letermovir in the ex vivo human cotyledon perfusion model.
Valentine FAURE-BARDON, France

16:15 Coffee Break
16:45 Treatment and prognosis of fetal and paediatric infections (Part 2) • Chairs: Catherine DONNER, Belgium; Giuliana SIMONAZZI, Italy;Dana WOLF, Israel
16:45 Treatment and prognosis of paediatric infection.
Suzanne LUCK, UK

17:10 Evaluation of cell mediated immunity (CMI) using the QuantiFERON-CMV test in congenital CMV infection (cCMV).
Concetta MARSICO, Italy

17:25 Prognostic value of magnetic resonance imaging in newborns with congenital cytomegalovirus infection.
Daniel BLÁZQUEZ-GAMERO, Spain

17:40 The role of CMV-DNA detection in cerebro-spinal fluid in newborns with congenital CMV infection: a 6-year experience of a tertiary care neonatal center.
Justyna CZECH-KOWALSKA, Poland

17:55 Valnoctamide rescues CMV-induced deafness in a murine model.
Sara ORNAGHI, Italy and USA

18:10 Management of congenital CMV-Infection: Updated recommendations in Germany.
Susanne MODROW, Germany

18:25 End of session
20:00 Dinner in town
Tuesday May 15th
08:30 Prevention of maternal infection and of vertical transmission • Chairs: Pascale HUYNEN, Belgium; Arnaud MARCHANT, Belgium; Corinne HUBINONT, Belgium
08:30 Prevention of maternal infection and of vertical transmission.
Paul GRIFFITHS, UK

08:55 Development of a digital antenatal educational intervention to reduce the risk of acquisition of CMV in pregnancy: Working in partnership with pregnant women and families affected by CMV.
Christine JONES, UK

09:10 A multiparametric approach to identify specific immune profiles controlling HCMV vertical transmission from primary infected pregnant women.
Fabienne PIRAS-DOUCE, France

09:25 CMV vaccines, an update.
Ben VAN DER ZEIJST, The Netherlands

09:50 A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.
Miriam REUSCHENBACH, Germany

10:05 HCMV receptors identification by unbiased screening.
Laurent PEREZ, Switzerland

10:20 Coffee break
10:50 Prevention of maternal infection and of vertical transmission (part 2) • Chairs: Pascale HUYNEN, Belgium; Arnaud MARCHANT, Belgium; Corinne HUBINONT, Belgium
10:50 Towards the development of antibody-based immunoprophylaxis of congenital CMV infection.
Michael SCHMID, Switzerland

11:15 Impact of pharmacokinetics on the HIG efficiency to prevent maternofetal CMV transmission.
Klaus HAMPRECHT, Germany

11:30 Changed expression of angiogenic factors following HCMV-vertical transmission - Results from serum and amniotic fluid samples.
Lukas Edgar Maximilien PENKA, Germany

11:45 Lunch and posters
13:15 Clinical and epidemiological studies and clinical registries in Europe • Chairs: Ina FOULON, Belgium; Vana PAPAEVANGELOU, Greece
13:15 Introduction. Mapping the congenital CMV related clinical and epidemiological research capacity in Europe.
Suzanne SMIT, Belgium

13:30 The CROCUS study (Consequences and Risk factors Of congenital CytomegalovirUS): the strengths and limitations of this retrospective cohort study.
Ann VOSSEN, The Netherlands

13:45 Congenital CMV in France, databases, epidemiology and practices.
Sophie ALAIN, France

14:00 Hearing loss in children with a congenital cytomegalovirus infection: a 22-year survey.
Ina FOULON, Belgium

14:15 Epidemiology and prevention of non-primary human cytomegalovirus infection in pregnancy (CHILd study).
Daniele LILLERI, Italy

14:30 Introduction. Registries in Europe and the Spanish experience.
Daniel BLÁZQUEZ-GAMERO, Spain

14:45 ECCI registry: Together we rule.
Suzanne LUCK, UK

15:00 COIN Project: Standardising outcomes to reduce research waste.
James WEBBE, UK

15:15 Conducting a registry for children with congenital cytomegalovirus infection in Flanders: results, strengths and limitations.
Annelies KEYMEULEN, Belgium

15:30 Panel discussion. The future of congenital CMV research in Europe. • Arnaud MARCHANT, Belgium; Pamela VALLELY, UK; Elizaveta PADALKO, Belgium
16:30 End of meeting